Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
Fiche publication
Date publication
septembre 2019
Journal
Clinical colorectal cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi, Dr VIENOT Angélique
Tous les auteurs :
Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F
Lien Pubmed
Résumé
FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcomes.
Mots clés
Clinical parameters, FOLFIRINOX, Laboratory parameters, Prognosis, Risk categories
Référence
Clin Colorectal Cancer. 2019 Sep 4;: